CD274 and gastric cancer: In the same direction, not focusing on gastric cancer patients, the KEYNOTE-590 demonstrated that addition of Pembrolizumab to chemotherapy in first-line treatment improved OS and PFS in GEJ adenocarcinoma patients with a PD-L1 CPS ≥ 10 compared to chemotherapy alone [68].